Evidence network for deaths_(OS)

1SOLAR-1 (patients with PIK3CA mutant status), 20191PALOMA-3, 20161MONARCH 2, 20202E2112, 2021 ENCORE301, 20131MONALEESA-3, 20181BELLE-2 (full population), 20171NCT02756364 (sapanisertib weekly), 20221NCT02187991 - HR-positive and HER2-negative cohort, 20211QUILT-2.015, 20131Huang, 2020fulvestrantendocrine therapyexemestanepaclitaxelchemotherapycapecitabineplaceboalpelisib plus fulvestrantpalbociclib plus fulvestrantribociclib plus endocrine therapyabemaciclib plus fulvestrantentinostat plus exemestaneribociclib plus fulvestrantbuparlisib plus fulvestrantsapanisertib plus fulvestrantdalpiciclib plus fulvestranttucidinostat plus exemestanealisertib plus paclitaxelganitumab plus endocrine therapyOBI-822/OBI-821 plus cyclophosphamidemetformincelecoxib plus endocrine therapydirect evidencenetwork meta-analysis
T vs. C fulvestrantendocrine therapyexemestanepaclitaxelchemotherapycapecitabineplaceboalpelisib plus fulvestrantpalbociclib plus fulvestrantribociclib plus endocrine therapyabemaciclib plus fulvestrantentinostat plus exemestaneribociclib plus fulvestrantbuparlisib plus fulvestrantsapanisertib plus fulvestrantdalpiciclib plus fulvestranttucidinostat plus exemestanealisertib plus paclitaxelganitumab plus endocrine therapyOBI-822/OBI-821 plus cyclophosphamidemetformincelecoxib plus endocrine therapy
fulvestrant---NANANANANANANANANANANANANANANANANANANANANA
endocrine therapyNA---NANANANANANANANANANANANANANANANANANANANA
exemestaneNANA---NANANANANANANANANANANANANANANANANANANA
paclitaxelNANANA---NANANANANANANANANANANANANANANANANANA
chemotherapyNANANANA---NANANANANANANANANANANANANANANANANA
capecitabineNANANANANA---NANANANANANANANANANANANANANANANA
placeboNANANANANANA---NANANANANANANANANANANANANANANA
alpelisib plus fulvestrantNANANANANANANA---NANANANANANANANANANANANANANA
palbociclib plus fulvestrantNANANANANANANANA---NANANANANANANANANANANANANA
ribociclib plus endocrine therapyNANANANANANANANANA---NANANANANANANANANANANANA
abemaciclib plus fulvestrantNANANANANANANANANANA---NANANANANANANANANANANA
entinostat plus exemestaneNANANANANANANANANANANA---NANANANANANANANANANA
ribociclib plus fulvestrantNANANANANANANANANANANANA---NANANANANANANANANA
buparlisib plus fulvestrantNANANANANANANANANANANANANA---NANANANANANANANA
sapanisertib plus fulvestrantNANANANANANANANANANANANANANA---NANANANANANANA
dalpiciclib plus fulvestrantNANANANANANANANANANANANANANANA---NANANANANANA
tucidinostat plus exemestaneNANANANANANANANANANANANANANANANA---NANANANANA
alisertib plus paclitaxelNANANANANANANANANANANANANANANANANA---NANANANA
ganitumab plus endocrine therapyNANANANANANANANANANANANANANANANANANA---NANANA
OBI-822/OBI-821 plus cyclophosphamideNANANANANANANANANANANANANANANANANANANA---NANA
metforminNANANANANANANANANANANANANANANANANANANANA---NA
celecoxib plus endocrine therapyNANANANANANANANANANANANANANANANANANANANANA---

pathologies: 353,358,359 - treatments: 1435 result logic